https://nighthawkrottweilers.com/

Business

AbbVie Buyer Allergan is not the right means for the stock

[ads1]




In the six years since the Abbvie split from Abbott Laboratories, the company has been heading for a cliff: the end of US patent security for its criminal substance Humira.

Sale of Humira, Treating Rheumatoid Arthritis and a Dozen Other Diseases, accounts for more than half of AbbVie's annual revenue. With the drug losing patent security in the United States in 2023, the company has been running for a short time to find out how to fill that hole hole.



Source link

Back to top button

mahjong slot

https://covecasualrestaurant.com/

sbobet

https://mascotasipasa.com/

https://americanturfgrass.com/

https://www.revivalpedia.com/

https://clubarribamidland.com/

https://fishkinggrill.com/